Machteld Wymenga - Department of Oncology, Medisch Spectrum Twente

基本信息

浏览量：35

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1535O Cost and Value of EMA-registered Checkpoint Inhibitors for Solid Tumours in the Netherlands

A.H. Huisman,S. Koole,M. Wymenga, A. Pisters, H. Gelderblom, S.B. van Waalwijk van Doorn-Khosrovani

Annals of Oncology（2024）

引用0浏览0引用

LBA14 Intensified Alkylating Chemotherapy with Autologous Stem Cell Rescue (IACT) or Conventional Chemotherapy Followed by Olaparib (CCT-O) in Stage III, HER2-negative, Homologous Recombination Deficient (HRD) Breast Cancer (BC): Survival Results of the Randomized-Controlled SUBITO Trial

S. Linn, R.L. Seefat,V. De Jong,S.B. Vliek,S. Balduzzi,R.M. Bijlsma,M. Jongen-Lavrencic,I. Mandjes, M. Delfos,M. Schot, M.M. van Rosmalen,V. Retel,I. Eekhout, E. Kuip, A. Gonçalves,J. Nuver,M. Wymenga,I.R. Konings,V. Tjan-Heijnen, A. Jager

Annals of Oncology (2024)

引用0浏览0引用

750P PFS2 and Adjustment of Overall Survival (OS) for Subsequent Anticancer Therapy in Patients (pts) with Primary Advanced or Recurrent Endometrial Cancer (pa/rec) Treated with Dostarlimab Plus Chemotherapy or Chemotherapy Alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY Trial

B.M. Slomovitz, N. Raaschou-Jensen,R.L. Coleman,L. Gilbert,M.A. Powell,D. Cibula,S. Ghamande,L. Zavallone,A.A. Mendivil,B. Ataseven,D. Black,M. Wymenga,C. Billingsley, L.J. Willmott,C. McCourt, I. Podzielinski, O. Doehring, J. Garside,T.J. Herzog,M.R. Mirza

Annals of Oncology (2023): S514-S515

引用0浏览0引用

1312O from Regulating Off-Label Use to Creating an Environment for Drug Repurposing in Oncology

S. van Waalwijk van Doorn-Khosrovani, A. Pisters, E. Breugel,L. Timmers,E. E. Voest,H. Bloemendal,F. A. Eskens,M. Wymenga

Annals of Oncology（2022）

引用0浏览0引用

761PA Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer

K. Lee,Remco J. Molenaar,Remy Klaassen,Maarten F. Bijlsma,Mariëtte J. Weterman,Dick J. Richel,M. Wymenga,H.W.M. van Laarhoven,J.W. Wilmink

Annals of Oncology（2017）

引用4浏览0引用

OncoSTRIP for Optimizing Pharmacotherapy in Elderly Oncology Patients with Polypharmacy

T. Oude Munnink,J. de Vries, R. Schaafsma,M. Wymenga,H. Colen

Annals of Oncology（2016）

引用0浏览0引用

Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor

G. Bouma,E. De Vries,M. Wymenga,A. Walenkamp

NEUROENDOCRINOLOGY（2014）

引用0浏览0引用

Platinum-Based Combination Chemotherapy in the Treatment of Older Non-Small Cell Lung Cancer (nsclc) Patients (pts): is There A Role for Complete Geriatric Assessment (cga)? Final Results from the Prospective Multicenter Nvalt-3 Study

M. Wymenga,B. Biesma,A. Vincent,O. Dalesio,H. Groen

Journal of clinical oncology（2009）

引用3浏览0引用

Platinum-based combination chemotherapy in the treatment of older non-small cell lung cancer (NSCLC) patients (pts)

M. Wymenga,Bonne Biesma,Andrew D. Vincent,Otilia Dalesio,Hendricus Groen

Journal of Clinical Oncology（2009）

引用22浏览0引用

Can Baseline Complete Geriatric Assessment (CGA) Predict Toxicity in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients (pts) Receiving Combination Chemotherapy? Results from the First 100 Pts in the Prospective Multicenter NVALT-3 Study

M. Wymenga,B. Biesma,A. Vincent,O. Dalesio,J. Stigt,H. Smit,H. Groen

Journal of clinical oncology（2007）

引用4浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn